Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Oncology

Replicate Bioscience raises $40 million for RNA therapies

by Ryan Cross
September 10, 2021 | A version of this story appeared in Volume 99, Issue 33

 

Replicate Bioscience has launched with $40 million to develop self-replicating RNA therapies. Replicate has engineered viral RNA to deliver instructions for making proteins, such as antibodies and cytokines, to treat conditions including cancer and autoimmune diseases. The RNA molecules are designed to multiply on their own inside cells, which the firm hopes will make them effective at small doses. The approach is based partly on work that cofounders Nathaniel Wang and Andrew Geall did while at Synthetic Genomics and Novartis, respectively.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.